You are here: Industry Insights > cancer

News List

Studying unstable chromosomes can help predict cancer relapse, says Cancer Research UK pharmaceutical-technology
April 28, 2017
Cancer Research UK-funded TRACERx lung cancer study has claimed that unstable chromosomes within lung tumours ...
Blood test able to detect cancer a year in advance pharmafile
April 28, 2017
A team at the Francis Crick Institute, based in London, has discovered a new way of analysing blood in patients...
Money Pressures Mount When a Spouse Gets Cancer drugs.com
April 28, 2017
Family income can take a big hit when a wife or husband cares for a spouse with cancer, researchers report.
UK NCRI introduces five-year strategy to advance cancer research pharmaceutical-technology
April 27, 2017
UK NCRI introduces five-year strategy to advance cancer research - Pharmaceutical Technology
FDA condemns 14 companies selling fraudulent cancer 'cures' online pharmafile
April 27, 2017
The FDA has struck out against a wave of companies offering cancer treatments online which fraudulently...
One third of cancer cases in England diagnosed as emergency pharmatimes
April 26, 2017
More than one third (34 percent) of patients with cancer diagnosed as an emergency in England had not visited their GP beforehand...
Oxford Cancer Biomarkers licenses rights to China for three colorectal cancer tests biospectrumasia
April 25, 2017
Oxford Cancer Biomarkers (OCB) said it will expand the use of three of its in vitro diagnostic tests for colorectal cancer into China through a partnership with MBM.
England “really is not a good place” to get cancer, BMS UK General Manager says pharmafile
April 25, 2017
Bristol-Myers Squibb’s UK General Manager Ben Hickey has slammed NICE over its assessment criteria and process in
AbbVie’s experimental cancer drug hits wall in clinical study pharmafile
April 21, 2017
AbbVie have released that two Phase 3 trials of its experimental cancer drug, veliparib, missed both of their primary...
AbbVie’s PARP inhibitor fails in PhIII trials pharmatimes
April 21, 2017
AbbVie’s experimental PARP inhibitor veliparib has failed to meet key targets in two late-stage studies testing its potential in lung and breast cancer.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 87 88 Next page